A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
<h4>Background</h4>MVA85A and AERAS-402 are two clinically advanced viral vectored TB vaccine candidates expressing Mycobacterium tuberculosis antigens designed to boost BCG-induced immunity. Clinical trials with candidate malaria vaccines have demonstrated that adenoviral vector based p...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0141687&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850125019342962688 |
|---|---|
| author | Sharon Sheehan Stephanie A Harris Iman Satti David A Hokey Veerabadran Dheenadhayalan Lisa Stockdale Zita-Rose Manjaly Thomas Alice Minhinnick Morven Wilkie Samantha Vermaak Joel Meyer Matthew K O'Shea Maria Grazia Pau Isabella Versteege Macaya Douoguih Jenny Hendriks Jerald Sadoff Bernard Landry Paul Moss Helen McShane |
| author_facet | Sharon Sheehan Stephanie A Harris Iman Satti David A Hokey Veerabadran Dheenadhayalan Lisa Stockdale Zita-Rose Manjaly Thomas Alice Minhinnick Morven Wilkie Samantha Vermaak Joel Meyer Matthew K O'Shea Maria Grazia Pau Isabella Versteege Macaya Douoguih Jenny Hendriks Jerald Sadoff Bernard Landry Paul Moss Helen McShane |
| author_sort | Sharon Sheehan |
| collection | DOAJ |
| description | <h4>Background</h4>MVA85A and AERAS-402 are two clinically advanced viral vectored TB vaccine candidates expressing Mycobacterium tuberculosis antigens designed to boost BCG-induced immunity. Clinical trials with candidate malaria vaccines have demonstrated that adenoviral vector based priming immunisation, followed by MVA vector boost, induced high levels of immunity. We present the safety and immunogenicity results of the first clinical trial to evaluate this immunisation strategy in TB.<h4>Methods</h4>In this phase 1, open-label trial, 40 healthy previously BCG-vaccinated participants were enrolled into three treatment groups and vaccinated with 1 or 2 doses of AERAS-402 followed by MVA85A; or 3 doses of AERAS-402.<h4>Results</h4>Most related adverse events (AEs) were mild and there were no vaccine related serious AEs. Boosting AERAS-402 with MVA85A significantly increased Ag85A-specific T-cell responses from day of vaccination. Two priming doses of AERAS-402 followed by MVA85A boost, resulted in a significantly higher AUC post-peak Ag85A response compared to three doses of AERAS-402 and historical data with MVA85A vaccination alone. The frequency of CD8+ T-cells producing IFN-γ, TNF-α and IL-2 was highest in the group receiving two priming doses of AERAS-402 followed by MVA85A.<h4>Conclusions</h4>Vaccination with AERAS-402 followed by MVA85A was safe and increased the durability of antigen specific T-cell responses and the frequency and polyfunctionality of CD8+ T-cells, which may be important in protection against TB. Further clinical trials with adenoviral prime-MVA85A boost regimens are merited to optimise vaccination intervals, dose and route of immunisation and to evaluate this strategy in the target population in TB high burden countries.<h4>Trial registration</h4>ClinicalTrials.gov NCT01683773. |
| format | Article |
| id | doaj-art-5b7a79c4e6d34056983f405b41737c6f |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-5b7a79c4e6d34056983f405b41737c6f2025-08-20T02:34:12ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011011e014168710.1371/journal.pone.0141687A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.Sharon SheehanStephanie A HarrisIman SattiDavid A HokeyVeerabadran DheenadhayalanLisa StockdaleZita-Rose Manjaly ThomasAlice MinhinnickMorven WilkieSamantha VermaakJoel MeyerMatthew K O'SheaMaria Grazia PauIsabella VersteegeMacaya DouoguihJenny HendriksJerald SadoffBernard LandryPaul MossHelen McShane<h4>Background</h4>MVA85A and AERAS-402 are two clinically advanced viral vectored TB vaccine candidates expressing Mycobacterium tuberculosis antigens designed to boost BCG-induced immunity. Clinical trials with candidate malaria vaccines have demonstrated that adenoviral vector based priming immunisation, followed by MVA vector boost, induced high levels of immunity. We present the safety and immunogenicity results of the first clinical trial to evaluate this immunisation strategy in TB.<h4>Methods</h4>In this phase 1, open-label trial, 40 healthy previously BCG-vaccinated participants were enrolled into three treatment groups and vaccinated with 1 or 2 doses of AERAS-402 followed by MVA85A; or 3 doses of AERAS-402.<h4>Results</h4>Most related adverse events (AEs) were mild and there were no vaccine related serious AEs. Boosting AERAS-402 with MVA85A significantly increased Ag85A-specific T-cell responses from day of vaccination. Two priming doses of AERAS-402 followed by MVA85A boost, resulted in a significantly higher AUC post-peak Ag85A response compared to three doses of AERAS-402 and historical data with MVA85A vaccination alone. The frequency of CD8+ T-cells producing IFN-γ, TNF-α and IL-2 was highest in the group receiving two priming doses of AERAS-402 followed by MVA85A.<h4>Conclusions</h4>Vaccination with AERAS-402 followed by MVA85A was safe and increased the durability of antigen specific T-cell responses and the frequency and polyfunctionality of CD8+ T-cells, which may be important in protection against TB. Further clinical trials with adenoviral prime-MVA85A boost regimens are merited to optimise vaccination intervals, dose and route of immunisation and to evaluate this strategy in the target population in TB high burden countries.<h4>Trial registration</h4>ClinicalTrials.gov NCT01683773.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0141687&type=printable |
| spellingShingle | Sharon Sheehan Stephanie A Harris Iman Satti David A Hokey Veerabadran Dheenadhayalan Lisa Stockdale Zita-Rose Manjaly Thomas Alice Minhinnick Morven Wilkie Samantha Vermaak Joel Meyer Matthew K O'Shea Maria Grazia Pau Isabella Versteege Macaya Douoguih Jenny Hendriks Jerald Sadoff Bernard Landry Paul Moss Helen McShane A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults. PLoS ONE |
| title | A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults. |
| title_full | A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults. |
| title_fullStr | A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults. |
| title_full_unstemmed | A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults. |
| title_short | A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults. |
| title_sort | phase i open label trial evaluating the safety and immunogenicity of candidate tuberculosis vaccines aeras 402 and mva85a administered by prime boost regime in bcg vaccinated healthy adults |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0141687&type=printable |
| work_keys_str_mv | AT sharonsheehan aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT stephanieaharris aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT imansatti aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT davidahokey aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT veerabadrandheenadhayalan aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT lisastockdale aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT zitarosemanjalythomas aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT aliceminhinnick aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT morvenwilkie aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT samanthavermaak aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT joelmeyer aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT matthewkoshea aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT mariagraziapau aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT isabellaversteege aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT macayadouoguih aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT jennyhendriks aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT jeraldsadoff aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT bernardlandry aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT paulmoss aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT helenmcshane aphaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT sharonsheehan phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT stephanieaharris phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT imansatti phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT davidahokey phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT veerabadrandheenadhayalan phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT lisastockdale phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT zitarosemanjalythomas phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT aliceminhinnick phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT morvenwilkie phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT samanthavermaak phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT joelmeyer phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT matthewkoshea phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT mariagraziapau phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT isabellaversteege phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT macayadouoguih phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT jennyhendriks phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT jeraldsadoff phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT bernardlandry phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT paulmoss phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults AT helenmcshane phaseiopenlabeltrialevaluatingthesafetyandimmunogenicityofcandidatetuberculosisvaccinesaeras402andmva85aadministeredbyprimeboostregimeinbcgvaccinatedhealthyadults |